TVAX Biomedical (TVAX) Sees IPO Price of $9-$11/Share
Tweet
Share
E-mail
TVAX Biomedical, Inc. (Nasdaq: TVAX), filed an amended registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. TVAX plans to sell 2 million shares and sees an offering price of $9 - $11 per share. TVAX Biomedical plans to list on the Nasdaq Capital Market under the ticker "TVAX."
The offering is being made through Roth Capital Partners, Cantor Fitzgerald & Co., and Aegis Capital Corp.
TVAX is a biotechnology company focused on the development of targeted cell-based immunotherapies for the treatment of cancer.
The offering is being made through Roth Capital Partners, Cantor Fitzgerald & Co., and Aegis Capital Corp.
TVAX is a biotechnology company focused on the development of targeted cell-based immunotherapies for the treatment of cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scribe Therapeutics prices IPO at $15 per share on Nasdaq
- China Pharma Holdings closes $5M direct offering at $2 per share
- Maison Solutions to form AI subsidiary with 90% ownership stake
Create E-mail Alert Related Categories
IPOsRelated Entities
Cantor Fitzgerald, Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
